Immatics biotechnologies receives $20m grant from the State of Texas for the development of immunotherapies against cancer

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded a grant of $19.7m to Immatics Biotechnologies for the development of personalized adoptive cellular immunotherapies against novel and proprietary targets discovered by Immatics. This funding will support innovative projects  to be developed by a US-based subsidiary of Immatics Biotechnologies GmbH in Houston, Texas. The work will be conducted in close collaboration with MD Anderson Cancer Center (Houston), the world’s largest cancer center. Immaticswill provide more detail on its US plans and development programs in cellular immunotherapies in the near future.

Link to announcement on website CPRIT

Link to announcement on website MD Anderson Cancer Center

Media contact: Please approach us at media[at]immatics.com or call +49 (7071) 5397-0.

Press Contact

Dr Nikola Wiegeler

Press contact,
Immatics Biotechnologies GmbH

+49 7071 5397-0

Go back